By a News Reporter-Staff News Editor at Biotech Week -- Fresh data on Stargardt Disease are presented in a new report. According to news reporting from Cleveland, Ohio, by NewsRx journalists, research stated, "A systems pharmacological approach that capitalizes on the characterization of intracellular signaling networks can transform our understanding of human diseases and lead to therapy development. Here, we applied this strategy to identify pharmacological targets for the treatment of Stargardt disease, a severe juvenile form of macular degeneration."
The news correspondents obtained a quote from the research from Case Western Reserve University, "Diverse GPCRs have previously been implicated in neuronal cell survival, and crosstalk between GPCR signaling pathways represents an unexplored avenue for pharmacological intervention. We focused on this receptor family for potential therapeutic interventions in macular disease. Complete transcriptomes of mouse and human samples were analyzed to assess the expression of GPCRs in the retina. Focusing on adrenergic (AR) and serotonin (5-HT) receptors, we found that adrenoceptor a 2C (Adra2c) and serotonin receptor 2a (Htr2a) were the most highly expressed. Using a mouse model of Stargard.t disease, we found that pharmacological interventions that targeted both GPCR signaling pathways and adenylate cyclases (ACs) improved photoreceptor cell survival, preserved photoreceptor function, and attenuated the accumulation of pathological fluorescent deposits in the retina."
According to the news reporters, the research concluded: "These findings demonstrate a strategy for the identification of new drug candidates and FDA-approved drugs for the treatment of monogenic and complex diseases."
For more information on this research see: Systems pharmacology identifies drug targets for Stargardt disease-associated retinal degeneration. Journal of Clinical Investigation, 2013;123(12):5119-5134. Journal of Clinical Investigation can be contacted at: Amer Soc Clinical Investigation Inc, 35 Research Dr, Ste 300, Ann Arbor, MI 48103, USA (see also Stargardt Disease).
Our news journalists report that additional information may be obtained by contacting Y. Chen, Case Western Reserve University, Sch Med, Dept. of Ophthalmol, Cleveland, OH 44160, United States. Additional authors for this research include G. Palczewska, D. Mustafi, M. Golczak, Z.Q. Dong, O. Sawada, T. Maeda, A. Maeda and K. Palczewski.
Keywords for this news article include: Ohio, Pharmaceuticals, Drugs, Cleveland, Treatment, Pharmacology, Therapeutics, United States, Stargardt Disease, Macular Degeneration, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC